Navigation Links
Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
Date:2/14/2011

sal osteoporosis later this year, and a Marketing Authorization Application to the European Medicines Agency next year.

Calcitonin is currently approved for the treatment of postmenopausal osteoporosis, but its use has been limited by the fact that it is currently available only in intranasal and injectable forms.  Tarsa's oral calcitonin product has been shown in prior clinical studies to deliver the desired blood levels of calcitonin and reduce levels of biomarkers of bone resorption.  

Dr. David Krause, Chief Medical Officer of Tarsa, commented, "Osteoporosis is a common condition that poses major health risks to individuals as they age, but it can be both treated and prevented.  Calcitonin has a long history of safety and efficacy as an osteoporosis therapy, and we believe the availability of Tarsa's easy-to-use, once-daily oral calcitonin tablet will be welcomed by the many health care providers and patients seeking additional treatment options, especially in view of continuing concerns about potential long-term safety issues with other popular classes of osteoporosis drugs."

Tarsa's Phase II prevention trial will also explore the optimal dosing regimen for oral calcitonin by administering the tablets either with the evening meal or at bedtime.  Calcitonin helps maintain bone mass by acting on osteoclasts to limit bone resorption.  Most bone resorption occurs while individuals are sleeping; therefore some researchers believe that nighttime administration would be ideal for an anti-resorptive agent such as calcitonin.  

For more information on the Phase II osteoporosis prevention trial, visit: http://www.clinicaltrials.gov/ct2/show/NCT01292187?term=tarsa&rank=2

About Tarsa TherapeuticsTarsa Therapeutics is developing an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteo
'/>"/>

SOURCE Tarsa Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
2. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
3. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
4. Prime Therapeutics President and CEO Eric Elliott Presents Keynote Address at 2011 PCMA Managed Markets Educational Forum
5. NewCardio Study of QTinno Accuracy Selected for Presentation at the National Scientific Meeting of the American Society of Clinical Pharmacology and Therapeutics
6. DSM and NKT Therapeutics Sign Contract for Lead Product Development and Manufacture
7. JumpStart Ventures and Cleveland Clinic Invest in SironRX Therapeutics
8. Amarin to Present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
9. CardioVascular BioTherapeutics Submits FDA Application for Fast Track Status for CVBT-141B, CVBTs Biological Treatment for Diabetes Patients
10. PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients
11. Mederi Therapeutics Announces Receipt of FDA 510(k) Clearance for the MDRF1 Radiofrequency Generator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... Nov. 23, 2014  Aurobindo Pharma USA ... Capsules, USP 300 mg 100-count bottles to the consumer ... some empty capsules. Empty capsules could result ... consequences that could range from no effect, short term ... epilepticus (long period seizures) that could be life-threatening. Aurobindo ...
(Date:11/22/2014)... , Nov. 21, 2014   Long Beach dentist , ... often called the gold standard in tooth replacement because they ... stable, long-lasting way to restore and preserve smiles and improve ... replace a missing tooth or as a part of a ... look and feel of a smile. The loss ...
(Date:11/22/2014)... HILL, N.C. , Nov. 21, 2014 /PRNewswire/ ... healthcare system. Undoubtedly, the growing influence of patients ... spend for marketing interactions. Now, more than ever, ... retain patients for medical products is essential. ... firm, Best Practices, LLC, benchmarked companies spent about ...
Breaking Medicine Technology:Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2Long Beach Dentist, Dr. Rassouli, is Now Offering Dental Implants 2New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2
... 18 Epiphany Biosciences announced results from its Phase ... shingles (herpes zoster) infection. The study,s primary endpoint ... in terms of time to complete crusting of the ... randomized into 3 arms: 1 gram of once-daily ...
... Nov. 18 Covance Inc. (NYSE: CVD ), ... it entered into a biomarker alliance and services agreement with ... biomarker testing to the pharmaceutical industry. , Subject to the ... exclusive third-party provider of multiplexed protein biomarker testing services, and ...
Cached Medicine Technology:Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles. 2Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles. 3Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc. 2Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc. 3Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc. 4
(Date:11/23/2014)... November 23, 2014 Syngenta lawsuits are ... behalf of farmers and agribusinesses that have allegedly incurred ... commercialize Agrisure Viptera and Agrisure Duracade, genetically modified ... approved for sale in China. According to a report ... virtually ban U.S. corn imports. Because China is the ...
(Date:11/23/2014)... Lake City, Utah (PRWEB) November 23, 2014 ... individual health insurance reimbursement for small businesses, announced ... new book, The End of Employer-Provided Health Insurance. ... health insurance is the greatest financial risk facing ... challenge facing U.S. employers, small and large, when ...
(Date:11/22/2014)... Cancer researchers in New York and Minnesota ... tunnels and the growth and spread of mesothelioma. ... the Surviving Mesothelioma website. , Doctors at Memorial ... have just released their study on tunneling nanotubes (TnTs), ... They found that mesothelioma cells contain many ...
(Date:11/22/2014)... A classic black prom dress will never go out of ... unveiled its new items of black prom gowns . ... big discount, up to 70% off. People throughout the world ... prom dresses, made with the best materials, can make wearers ... customers, the company provides these beautiful outfits in a huge ...
(Date:11/22/2014)... Today, Dylan Queen, a renowned brand in wedding ... the business offers a wide range of special occasion ... allowing them to create multiple looks easily. , According ... collection of chic wedding dresses has been prepared for ... discounted rates now. Dylan Queen can always create what ...
Breaking Medicine News(10 mins):Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2Health News:New Black Prom Dresses from BellasDress.com 2Health News:Dylan Queen Introduces Its New Wedding Dresses 2
... SHENZHEN, China, Sept. 21 /PRNewswire-Asia/ -- ... or the "Company"), a leading,exporter of medical dressing and ... sponsored the "2009 China Medical Textile Industry,Forum -- Innovation ... China. , The organizer of ...
... , , LINCOLN, R.I., Sept. 21 ... Americans report problems with chronic pain; more than diabetes, heart disease, ... of chronic pain in the United States, including healthcare expenses, lost ... , "Despite the obvious impact on our society and ...
... , , BIRMINGHAM, Ala., ... today announced that it has been awarded a $77.2 million contract ... to complete Phase 3 development of its influenza neuraminidase inhibitor, intravenous ... , "We are very excited to continue working ...
... , PRINCETON, N.J., Sept. 21 ... Company), a late-stage biotechnology company, announced today that it has ... Institute of Allergy and Infectious Diseases (NIAID), a division of ... over a five-year period, the development of formulation and manufacturing ...
... , , INDIANAPOLIS, Sept. 21 ... in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who ... care as compared to placebo plus best supportive care. ... previous studies looking at the use of histology to tailor treatment ...
... , , , ... today announced U.S. Food & Drug Administration clearance to market ... is the first and only blood glucose monitor that plugs ... information that can help optimize diabetes management. The CONTOUR USB ...
Cached Medicine News:Health News:Winner Medical Solely Sponsored the 2009 China Medical Textile Industry Forum 2Health News:Winner Medical Solely Sponsored the 2009 China Medical Textile Industry Forum 3Health News:Measuring Pain from the Patient's Point of View 2Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 2Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 3Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 4Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 5Health News:DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 2Health News:DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 3Health News:DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 4Health News:DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 5Health News:DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 6Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 2Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 3Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 4Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 5Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 6Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 7Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 8Health News:Bayer Introduces CONTOUR USB - The First Blood Glucose Meter With Unique Plug & Play Diabetes Management Software 2Health News:Bayer Introduces CONTOUR USB - The First Blood Glucose Meter With Unique Plug & Play Diabetes Management Software 3Health News:Bayer Introduces CONTOUR USB - The First Blood Glucose Meter With Unique Plug & Play Diabetes Management Software 4Health News:Bayer Introduces CONTOUR USB - The First Blood Glucose Meter With Unique Plug & Play Diabetes Management Software 5
... Pediatric Sarmiento-style PTB tibial orthosis ... Lined with closed-cell foam at bony ... Selection of 3 modular footpiece/shoe insert ... patient. Stretch Velcro® design fits especially ...
... is a lightweight patient friendly brace utilizing the ... The Escort provides patients with a lightweight ... Superior comfort and improved patient compliance is ... Escort Hip brace is the result of ...
Distinct male and female designs for proper anatomical fit. Hip and pelvic components sized independently. Rigid posterior tongue minimizes pelvic rotation. Available in black or white plastic. Aggre...
Modular hip abduction system designed to provide superior fit, adjustability and functionality for optimum patient stability, comfort and compliance...
Medicine Products: